或能改善牛奶过敏婴儿健康状态的合生制剂
创作:周旸 审核:周旸 2019年02月18日
  • 纳入71名非IgE介导的牛奶过敏婴儿和51名健康婴儿,随机分成实验组和对照组,实验组连续8周食用含合生制剂的氨基酸基配方奶粉(AAF),超过70%的婴儿连续摄入该AFF达到26周;
  • 合生制剂含低聚果糖和短双歧杆菌M-16V;
  • 干预26周后,实验组中粪便中双歧杆菌的相对丰度显著增加,直肠真杆菌/球形梭状芽孢杆菌的丰度显著降低;
  • 实验组的皮肤药物使用以及耳部感染症状显著减少;
  • 实验组的基础临床症状、粪便异常症状较轻。
主编推荐语
周旸
牛奶过敏是婴儿常见过敏症状。本研究纳入71名非IgE介导的牛奶过敏婴儿和51名健康婴儿,发现长时间连续食用合生制剂可调整婴儿肠道菌群结构,改善健康状况。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!

A specific synbiotic-containing amino acid-based formula in dietary management of cow's milk allergy: a randomized controlled trial

一种含有合生元的氨基酸基配方奶粉在控制牛奶过敏中的作用:一项随机对照研究

10.1186/s13601-019-0241-3

2019-01-15, Article

Abstract & Authors:展开

Abstract:收起
Background: Here we report follow-up data from a double-blind, randomized, controlled multicenter trial, which investigated fecal microbiota changes with a new amino acid-based formula (AAF) including synbiotics in infants with non-immunoglobulin E (IgE)-mediated cow's milk allergy (CMA).
Methods: Subjects were randomized to receive test product (AAF including fructo-oligosaccharides and M-16V) or control product (AAF) for 8 weeks, after which infants could continue study product until 26 weeks. Fecal percentages of bifidobacteria and / group () were assessed at 0, 8, 12, and 26 weeks. Additional endpoints included stool markers of gut immune status, clinical symptoms, and safety assessments including adverse events and medication use.
Results: The trial included 35 test subjects, 36 controls, and 51 in the healthy reference group. Study product was continued by 86% and 92% of test and control subjects between week 8-12, and by 71% and 80%, respectively until week 26. At week 26 median percentages of bifidobacteria were significantly higher in test than control [47.0% vs. 11.8% ( < 0.001)], whereas percentages of were significantly lower [(13.7% vs. 23.6% ( = 0.003)]. Safety parameters were similar between groups. Interestingly use of dermatological medication and reported ear infections were lower in test versus control,  = 0.019 and 0.011, respectively. Baseline clinical symptoms and stool markers were mild (but persistent) and low, respectively. Symptoms reduced towards lowest score in both groups.
Conclusion: Beneficial effects of this AAF including specific synbiotics on microbiota composition were observed over 26 weeks, and shown suitable for dietary management of infants with non-IgE-mediated CMA. NTR3979.

First Authors:
Adam T Fox,Harm Wopereis

Correspondence Authors:
Marleen T J Van Ampting

All Authors:
Adam T Fox,Harm Wopereis,Marleen T J Van Ampting,Manon M Oude Nijhuis,Assad M Butt,Diego G Peroni,Yvan Vandenplas,David C A Candy,Neil Shah,Christina E West,Johan Garssen,Lucien F Harthoorn,Jan Knol,Louise J Michaelis

评论